Compare Merck & Co., Inc. (MRK) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Motorola Solutions Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Motorola Solutions Inc trades at $463.3 (market cap $76.62B). The key difference: Merck & Co., Inc. is far larger — about 4.8× Motorola Solutions Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | MSI | |
|---|---|---|
Market Cap | $366.28B | $76.62B |
Sector | Health | Technology |
52-Week High | $156.43 | $491.24 |
52-Week Low | $77.60 | $363.83 |
Enterprise Value | $413.04B | $85.53B |
Dividend Yield | 2.29% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Motorola Solutions (MSI) trades at $462.98, down 1.08% on the day, amid a bullish technical setup with strong support at $459. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth is steady, reaching $11.68 billion in 2025, while net income margin improved to 17.44%. Recent news highlights a $2 billion share repurchase authorization and the completion of the $1.5 billion D-Fend Solutions acquisition, expanding its counter-drone portfolio.
The outlook remains positive given analyst consensus favoring Buy ratings (70.59%) and a price target of $536.50, implying ~16% upside. Key risks include elevated valuation multiples (P/E 36.48) and significant investing cash outflows ($-5.16 billion in 2025) from acquisitions. Execution on integration and debt management will be critical for sustaining shareholder value amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
